5th GLOBAL FORUM ON NICOTINE

14th - 16th June 2018
Warsaw, Marriott Hotel

#GFN18
‘RETHINKING NICOTINE’
The conference team extends you a warm welcome to this the fifth Global Forum on Nicotine, held once again in the wonderful city of Warsaw.

The theme for this year is ‘Rethinking Nicotine’ and the diversity of the programme reflects the appetite that now exists to examine the changing methods and patterns of use, along with the emerging science relating to nicotine.

The landscape of legislation and regulation across the globe is still inconsistent, despite the science continuing to demonstrate the reduced risk between smoking and other manifestly safer ways for people to use and enjoy nicotine. The influence of consumer advocacy continues to grow and in places politicians are beginning to recognise the significance of tobacco harm reduction as an issue. Against this, the continued misrepresentation via some media sources continues to cast doubt in the minds of politicians and public at large. Reflecting this, in constructing the programme we have tried to incorporate a wide range of issues and perspectives, to create a space for open and constructive debate. As with previous editions of the conference, this includes contributions from leading scientists, public health professionals and thought leaders, consumers and manufacturers of safer nicotine products.

A new addition to the conference this year is the GFN Film Festival, which has been curated by Aaron Biebert, the Director of ‘A Billion Lives’. Films have been selected from a call for submissions and will be shown alongside the parallel sessions on Friday, with a prize being awarded to the best film being presented on Saturday in the closing session of the conference.

Following the success of the inaugural event last year, we are delighted also to have the second International Symposium on Nicotine Technology (ISoNTech) take place alongside the conference. Once again chaired by Professor Martin Jarvis, it will see scientists explain and demonstrate work that is going into developing new, safer nicotine products.

As ever there will be a large number of activities for networking during the three days, including the conference party and the conference reception, and we hope that you will take full advantage of these to renew old acquaintances, as well as making new ones.

The unique inclusive nature of the Global Forum continues to provide a platform for exchange and debate of often-contentious issues and this is made possible by the commitment of all who attend it to do so with an open mind and to examine the evidence in making decisions and judgements. This is the basis of our claim that the event is ‘the only place where science and policy meet’.

We hope that you will find your time at GFN informative and enjoyable. If you require any assistance during the event, please just ask at the registration desk and a member of the team will endeavour to help.

The Conference Team
Information for GFN participants

The conference is funded by registrations and has not received any sponsorship from manufacturers, distributors or retailers of nicotine products including pharmaceutical, electronic cigarette and tobacco companies.

This is a multi-stakeholder event – participants include consumers, scientists, regulators, manufacturers and distributors, public health professionals, policy analysts and parliamentarians. Inevitably there will be a wide range of views expressed. We ask you to observe a basic ‘house rule’ that every speaker – whether from the platform, or the audience - deserves to be listened to with courtesy.

GFN 2018 Vaping Policy

GFN supports the rights of consumers and encourages their participation in the conference.

The law in Poland regarding vaping in public places has changed, as a result of their interpretation and implementation of the EU TPD, and in the light of this we have had to alter the vaping policy for the conference.

As a result of the new law vaping is not permitted in the public places. The conference venue is deemed to be a public place – this includes the corridors, exhibition area, media rooms and the rooms used for sessions – and thus vaping is not permitted. This is not the organisers’ decision, it is the policy of the management of the premises, compliant with Polish law.

We have negotiated with the hotel that one room can be designated a vaping room. This will be the Kometa Room. Adjacent to the floor where the conference is taking place there is a terrace, which is covered and easily accessible for those who wish to use it, where vaping is also permitted.

We ask that all participants note and observe the policy during the course of the conference.

Filming and Photography

The conference welcomes commercial and non-commercial media coverage of the event, including film, photographic and audio recording. Filming and audio recording (excluding photography using small equipment such as mobile phones) in the session rooms is by permission of the organisers and should be done in an unobtrusive manner that does not impede the proceedings for participants. Unless otherwise agreed in writing, copyright in all images and recordings in the session rooms becomes joint copyright of the person, or organisation making the recording and the conference organisers. No film, images, or audio-recordings taken anywhere in the conference venue may be used in any commercial advertisement without the agreement of the organisers and those who appear in such media.

GFN Patron - Mr Hon Lik

Mr Hon Lik is the Chinese pharmacist who invented the modern electronic cigarette. In 2001, while using high-dose nicotine patches to help himself stop smoking, he devised a system on a large console, using food additives as solvents. The challenge was managing to scale the mechanism down to a miniature size, suitable for a hand-held cigarette-sized device, and getting the right dose of nicotine, while also getting the right odours from additives.

In 2000, he came up with the idea of using a piezoelectric ultrasound-emitting element to vaporize a pressurized jet of liquid containing nicotine diluted in a propylene glycol solution. Hon also proposed placing the liquid in a disposable plastic cartridge, which serves as a reservoir and mouthpiece. These inventions are the basis of the present-day electronic cigarettes. In 2003, Hon filed the first patent in 2003 in China for the device and the first electronic cigarette was manufactured that year in Beijing.
The Michael Russell Oration has been established as an annual event, delivered to honour the work and memory of Professor Michael Russell, one of the pioneers in the study of smoking behaviour, clinical interventions and public policy action, who died in 2009.

Michael Russell, a psychiatrist and research scientist, was a pioneer in the study of tobacco dependence and the development of treatments to help smokers quit. The enduring impact of his work is likely to place him among the foremost clinical public health scientists of the twentieth century.

He was born in Cape Town, South Africa, and whilst working in London at the Institute of Psychiatry between 1969 and 1998, he conducted a number of highly original studies that revolutionised our understanding of both the pharmacological and psychological basis of tobacco smoking. For public health the interventions and treatments he developed have had an enormous impact throughout the world, in reducing the morbidity and mortality caused by tobacco. In the UK his work formed much of the evidence base that inspired the new NHS Stop Smoking services, launched in the year after his retirement. He argued that while the tobacco industry remained free to market cigarettes, millions of lives would be prematurely ended, especially in the growing markets in developing countries, before sufficient numbers of smokers could quit.

Based on the knowledge that pure nicotine carries little health risk, but is the main reason why people smoke, he advocated the development and promotion of safer nicotine products to the exclusion of cigarettes, to reduce the majority of harm caused by ingesting the non-nicotine toxins in burning tobacco. Michael Russell is the person who did most to lay the foundations for tobacco harm reduction that drives much research in the field today.

A doctor, speaker, author, media presenter and health industry consultant, Dr Joe Kosterich wants you to be healthy and get the most out of life.

Joe writes for numerous medical and mainstream publications and is also a regular on radio and television in Australia. He is often called to give opinions in medico legal cases and he is also an adjunct professor (teaching) at the University of Western Australia. He is on the editorial advisory panel of Medical Forum Magazine and Reed Medical Conferences. ‘Dr Joe’ maintains a website and blog with health information and commentary. He self-published two books: Dr Joe’s DIY Health and 60 Minutes To Better Health.

Previously he held senior positions in the Australian Medical Association and sat on numerous industry and government boards. He has extensive corporate experience in the setting up and management of medical centres and in helping businesses maintain a healthy workforce. Through all this he continues to see patients as a General Practitioner each week.

His interest in e-cigarettes has come from listening to the experience of patients. This is both those struggling to quit smoking and those whose success has come from vaping.
POSTER PRESENTATIONS

Abdulkhakov, Sayar R.; Faizullin, Rashat I.; Rizvanov, Albert A.; Grigoryeva, Tatyana V.; Lapukhov, Leonid V.; Klassov, Andrey P.

The biomarkers of exposure levels after switching from conventional cigarettes to tobacco heating system

Adriaens, Karolien; Van Gucht, Dinska; Baeyens, Frank

Experimental trial on the effectiveness of heat-not-burn cigarettes compared to e-cigarettes and regular tobacco cigarettes: Effects on acute craving, withdrawal, positive and negative experiences

Beacher, Felix

Potential predictors of intended use of a novel heat-not-burn tobacco product

Blair, Paul Edmund

The negative impact of taxation on tobacco harm reduction

Boland, Veronica; Courtney, Ryan; Aiken, Alexandra; Stockings, Emily; Chen, Rory; Borland, Ron; Gartner, Coral; McRobbie, Hayden; Siahpush, Mohammad; Thomas, Dennis; Petrie, Dennis; Shakeshaft, Anthony; Farrell, Michael; Doran, Christopher; Mendelsohn, Colin; Zwar, Nicholas; Hall, Wayne; Mattick, Richard

Adding a vaporised nicotine product to standard behavioural treatment for low-socioeconomic status smokers: a randomised trial – a study protocol

Boland, Veronica; Stockings, Emily; Mattick, Richard; McRobbie, Hayden; Brown, Jamie; Courtney, Ryan

The methodological quality and effectiveness of technology-based smoking cessation interventions for disadvantaged groups: A systematic review and meta-analysis.

Breheny, Damien Michael; Adamson, Jason; Baxter, Andrew; Crooks, Ian; Joynson, Tomasz; Taylor, Mark; Thorne, David; Liu, Chuan; Murphy, James; Gaco, Marianna

Assessment of the glo(TM) tobacco heating product: traditional and 21st century toxicology approaches

Chrea, Christelle; Spies, Erica; Afolalu, Esther; Mainy, Nelly; Gallot, Sophie; Binggeli, Patricia; Clerc, Emilie; Weitkunat, Rolf; Salzberger, Thomas; Cana, Stefan; Acquadro, Catherine; Arnauld, Benoit; Brunei, Vanessa; Lambert, Jeremy; Marcuccilli, Celine; Abbetz-Webb, Linda; Rose, Jed; Fagerstrom, Karl

Assessing consumer responses to reduced risk products: experience at Philip Morris International in developing fit-for-purpose self-report instruments

Coburn, Steven; Forster, Mark; Wright, Christopher; Mariner, Derek; McAughey, John; Murphy, James; Proctor, Christopher

Assessment of the glo(TM) tobacco heating product: aerosol composition and environmental emissions

DDS, MSc, PhD, Amalya; Wibawa, Dr. Satriya; Karim, Muhammad Ilham

The social impact of electric cigarette users as an alternative to tobacco cigarettes from the health security perspective in West Java - Indonesia

Djurdjevic, Smilja D; Baker, Gizelle; Lida, T.; Konishi, E.; Ludicke, F.

Modeling the population health impact of introducing a reduced risk product into the Japan market

Dolfel, Rainer; Hallermann, Marc; Schmidt, Norbert Zillatron; Schuster, Peter; Maaß, Sabine

Retrospective survey on switching patterns of experienced vapers

Edmiston, Jeffery; Liang, Qiwei; Miller, Sandra; Liu, Jianmin; Zhao, Yuxi; Sarkar, Mahomadi

Exhaled breath levels of selected constituents from controlled use of MarkTen® e-vapor products in adult e-vapor users

Engqvist, Håkan; Sundström, Ingela; Espefält Westin, Ulrika; Bredenberg, Susanne

Liquid free ceramic dose units for nicotine vaping

Science posters - meet the poster presenters: Friday, 13:00 - 14:00
# POSTER PRESENTATIONS

<table>
<thead>
<tr>
<th>Board #</th>
<th>Title</th>
<th>Authors</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>115</td>
<td>Has smoking stigma transferred onto e-cigarettes?</td>
<td>Farrimond, Hannah; Abraham, Charles</td>
<td></td>
</tr>
<tr>
<td>116</td>
<td>Tobacco use, awareness and cessation among Malayali tribes, Yelagiri Hills, Tamil nadu, India.</td>
<td>Francis, Delfin Lovelina</td>
<td></td>
</tr>
<tr>
<td>117</td>
<td>Assessment of the glo(TM) tobacco heating product: clinical biomarkers of exposure</td>
<td>Gale, Nathan; McEwan, Mike; Eldridge, Alison; Errington, Graham; Murphy, James; Proctor, Christopher; Fearon, Ian</td>
<td></td>
</tr>
<tr>
<td>118</td>
<td>REClaiM: Relapse prevention using e-cigarettes in inpatient smokers discharged from a smoke-free mental health service – protocol for the development of a complex harm reduction intervention</td>
<td>Gentry, Sarah Victoria; Notley, Caitlin</td>
<td></td>
</tr>
<tr>
<td>119</td>
<td>HPHC analysis of eight flavors of a temperature-regulated nicotine salt-based ENDS product</td>
<td>Gilman, Ph.D., Gene; Johnson, M.S., Melissa; Martin, M.S., Alexandra; Misra, Ph.D., Manoj</td>
<td></td>
</tr>
<tr>
<td>120</td>
<td>Factors influencing farmers turning into tobacco cultivation in the Khulna Division of Bangladesh</td>
<td>Hasan, Khan Mehedi; Ahmed, Md. Firoz</td>
<td></td>
</tr>
<tr>
<td>121</td>
<td>Evaluation of biological and functional changes in healthy smokers after switching from cigarettes to Tobacco Heating System (THS) 2.2 for 6 months</td>
<td>Haziza, Christelle; Ansari, S. Michael; Lama, Nicola; Bosilkovska, Manja; Blanc, Nicolas; Skida, Dimitra; Ancerewicz, Jacek; Picavet, Patrick; Baker, Gizelle; Lüdicke, Frank</td>
<td></td>
</tr>
<tr>
<td>122</td>
<td>The effect of electronic nicotine delivery systems (ENDS) and new tobacco products on the risk of cardiovascular disease in people with high tobacco dependence</td>
<td>Kvasha, Olena; Sribna, Olga; Rafael, Dmytro</td>
<td></td>
</tr>
<tr>
<td>123</td>
<td>Product experience and risk perceptions in IQOS users: a cross-sectional survey in Japan</td>
<td>Langer, Peter; Sponsiello-Wang, Zheng; Prieto, Luis; Dobrynina, Maria; Skida, Dimitra; Camille, Nathalie; Weitkunat, Rolf; Lüdicke, Frank</td>
<td></td>
</tr>
<tr>
<td>124</td>
<td>Assessment of abuse potential of a moist smokeless tobacco product relative to cigarette and nicotine gum based on nicotine pharmacokinetics and subjective effect measures</td>
<td>Liu, Jianmin; Wang, Jingzhu; Liang, Qiwei; Sarkar, Mohamadi</td>
<td></td>
</tr>
<tr>
<td>125</td>
<td>Characterization of nicotine pharmacokinetics and subjective effects from a novel oral tobacco product in adult smokers</td>
<td>Liu, Jianmin; Wang, Jingzhu; Zhao, Yuxi; Sarkar, Mohamadi</td>
<td></td>
</tr>
<tr>
<td>126</td>
<td>Changes in biomarkers of exposure on switching from a conventional cigarette to tobacco heating products: a randomised, controlled study in healthy Japanese subjects</td>
<td>Murphy, James; Gale, Nathan; Proctor, Christopher</td>
<td></td>
</tr>
<tr>
<td>127</td>
<td>Evaluation of exposure to selected cigarette smoke constituents in healthy Japanese smokers after switching to novel tobacco product use from cigarette smoking in 5 days period</td>
<td>Nishihara, Daisuke; Nakaya, Kyoko; Takeshige, Yuki; Futamura, Yasuyuki</td>
<td></td>
</tr>
<tr>
<td>128</td>
<td>Reported patterns of vaping to support long term abstinence from smoking</td>
<td>Natley, Caitlin; Gentry, Sarah; Dawkins, Lynne; Holland, Richard; Ward, Emma; Jakes, Sarah</td>
<td></td>
</tr>
</tbody>
</table>

**Science posters - meet the poster presenters: Friday, 13:00 - 14:00**
### POSTER PRESENTATIONS

<table>
<thead>
<tr>
<th>Title</th>
<th>Board #</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chemical composition of myblu™ pod-system e-cigarette aerosols: a quantitative comparison with conventional cigarette smoke</td>
<td>129</td>
</tr>
<tr>
<td>Perceptions of the relative harm of electronic cigarettes compared with smoking in the USA: analysis of the Population Assessment of Tobacco and Health (PATH) study data, 2013-2015</td>
<td>130</td>
</tr>
<tr>
<td>The burden of deaths attributable to tobacco in different parts of the world: the role of different nicotine delivery systems</td>
<td>131</td>
</tr>
<tr>
<td>Estimation of second hand exposure levels from ENDS and conventional cigarette use using computational modeling</td>
<td>132</td>
</tr>
<tr>
<td>Randomized clinical trials and observational studies to assess health risks of reduced risk products</td>
<td>133</td>
</tr>
<tr>
<td>Global State of Tobacco Harm Reduction: mapping the global uptake of and response to safer nicotine products</td>
<td>134</td>
</tr>
<tr>
<td>Challenging a bad tobacco law: the legal challenge against the EU ban on snus</td>
<td>135</td>
</tr>
<tr>
<td>Environmental e-cig vapor issues in NASEM report</td>
<td>136</td>
</tr>
<tr>
<td>Nicotine metabolism rate decreases in smoking alcoholics during alcohol cessation therapy</td>
<td>137</td>
</tr>
<tr>
<td>“Cloud chasers” and “substitutes”: e-cigarettes, vaping subcultures and vaper identities</td>
<td>138</td>
</tr>
<tr>
<td>A multicenter, multiregional study on biological and functional changes in healthy adult smokers during one year of continuous smoking abstinence</td>
<td>139</td>
</tr>
</tbody>
</table>
## Satellite Events

### Satellite Meeting #1A (by invitation only)  
**09:00 - 13:30**  
**WAWEL**  
International Network of Nicotine Consumer Organisations general meeting

### Satellite Meeting #1B  
**14:30 - 16:30**  
**WAWEL**  
International Network of Nicotine Consumer Organisations - consumer session

### Satellite Meeting #2  
**12:00 - 16:00**  
**BALLROOM E**  
Addressing Combustible Tobacco Use in Persons with Psychiatric Challenges and Drug Using Populations

### Satellite Meeting #3  
**14:00 - 16:00**  
**BALLROOM F**  
Africa Harm Reduction Alliance - THR in Africa and other LMICs

---

## ISoNTech

For details of the ISoNTech event, see the ISoNTech reader

### Second International Symposium on Nicotine Technology  
**12:45 - 16:30**  
**BALLROOM CD**

### Networking & Lunch Break  
**13:25 - 14:20**  
**FOYER**

### Second International Symposium on Nicotine Technology, part 2  
**14:30 - 15:30**  
**BALLROOM CD**

### Networking & Coffee Break  
**15:20 - 15:50**  
**FOYER**

### Second International Symposium on Nicotine Technology, part 3  
**15:55 - 16:30**  
**BALLROOM CD**

### Media Briefing (by invitation only)  
**16:30 - 17:30**  
**WARS+SAWA**

### Refreshments & Networking  
**16:30 - 18:30**  
**FOYER**

---

## GFN Programme

### Michael Russell Memorial Oration 2018  
**18:30 - 19:45**  
**BALLROOM CD**

#### Introduction
Colin Mendelsohn *(Australia)*

#### Lecture
Joe Kosterich *(Australia)* - Rethinking Nicotine: new nicotine products, the media and the medical profession

#### Presentation of the INNCO Advocates of the Year Awards & the Michael Russell Award

#### INNCO Awards
*Introduced by Judy Gibson *(UK)*

#### MR Award
*Introduced by Gerry Stimson *(UK)*

### GFN Conference Social Event  
**19:45 - 24:00**  
**SPHINX Restaurant**
### Opening & Plenary 1: Rethinking nicotine - policy and science

**Time:** 9:00 - 11:00

**Location:** BALLROOM CD

**Chair:** Gerry Stimson (UK)

**Presenter:***
- **Joe Gitchell** (USA) - How to feel AND think about nicotine and those who use it
- **David Sweanor** (Canada) - The changing global nicotine market: disruptive technology hits the cigarette business
- **Sarah Jakes** (UK) - Rethinking why people like nicotine
- **Mohamadi Sarkar** (USA) - The role of smokeless tobacco in harm reduction - the divergence between consumer perceptions and scientific evidence
- **David Levy** (USA) - Modelling future impact of the uptake of e-cigarettes and other safer nicotine products

**Presenters:**
- **Joe Gitchell** (USA)
- **David Sweanor** (Canada)
- **Sarah Jakes** (UK)
- **Mohamadi Sarkar** (USA)
- **David Levy** (USA)

### Parallel Sessions

**Parallel Session 1: Policy, Advocacy and Practice Track: Country updates on tobacco harm reduction**

**Chair:** Nancy Sutthoff (New Zealand)

**Presenters:**
- **Karl Snaebjornsson** (Iceland) - Iceland, outlier in the middle of nowhere: smoking, vaping and snus
- **Colin Mendelsohn** (Australia) - The Australian Tobacco Harm Reduction Association - educating the public and health community about vaping
- **Hiroya Kumamaru** (Japan) - Japanese experience with heat-not-burn
- **Paweł Skutecki** (Poland) - Poland and the regulation of e-cigarettes
- **Roberto Sussman** (Mexico) - Regulation of electronic cigarettes in Mexico
- **Cecilia Kindstrand-Isaksson** (Sweden) - Reflections on change: is the tipping point in sight?

**Parallel Session 2: Science Track: Clinical and real world contexts for reduced harm nicotine products**

**Chair:** Grzegorz Król (Poland)

**Presenters:**
- **Richard Holliday** (UK) - E-cigarettes for smoking cessation within healthcare settings: patients’ perceptions and research feasibility
- **Thomas Brandon** (USA) - Using the balanced placebo trial design for parsing nicotine administration effects
- **Karolien Adriaens** (Belgium) - Experimental trial on the effectiveness of heat-not-burn cigarettes compared to e-cigarettes and regular tobacco cigarettes: effects on acute craving, withdrawal, positive and negative experiences
- **Daniel Frings** (UK) - How do vaping ads and anti-smoking messages affect attitudes towards both e-cigarettes and tobacco held by smokers, vapers, dual users and non-smokers?
- **Christelle Haziza** (Switzerland) - Changes in biological and functional markers after 6 months, in 3 populations: IQOS users, continued smokers, and smoking abstinence
- **Karl Lund** (Norway) - Perceptions of relative risk between cigarettes and snus, e-cigarettes and NRT-products

**Parallel Session 3: Film Festival Track: PART 1 - see Film Festival page for details**

**Chair:** Aaron Biebert (USA)
## FRIDAY, 15 JUNE

### 13:00 - 14:00
**Lunch Break & Science Posters**  
**Poster session 1 - meet the poster presenters**  
**FOYER**

### 14:00 - 15:30

<table>
<thead>
<tr>
<th>Parallel 4</th>
<th>Parallel Session 4</th>
<th>Parallel Session 5</th>
<th>Film Festival Parallel Session 6</th>
</tr>
</thead>
</table>
| **Policy, Advocacy and Practice Track:**  
**Regulation and consumers**  
**BALLROOM C**  
Chair | Robyn Gougelet *(USA)*  
Presenter | Peter Beckett *(UK)* - Two years of TPD: what have we learned?  
Presenter | Gregory Conley *(USA)* - Vapers, the vaping industry, and taxes: not always as they seem  
Presenter | Sudhanshu Patwardhan *(UK)* - The three country experiences with THR - consumer insights and product implications  
Presenter | Carrie Wade *(USA)* - Challenging bad literature for the good of public health  
Presenter | Julie Woessner *(USA)* - What Smokers Who Switched to Vapor Products Tell Us About Themselves  
Presenter | Marewa Glover *(New Zealand)* - Recognising vapers’ knowledge as a lay epidemiology and collaborating with them to reduce smoking-related harm  

### 15:30 - 16:00
**Break**  
**FOYER**

### 16:00 - 17:30
**Panel Discussion: Who can we trust? Evidence and promises**  
**BALLROOM CD**

| Moderator | Martin Cawley *(UK)*  
Panelist | Amy Fairchild *(USA)*  
Panelist | Laura Leigh Oyler *(USA)*  
Panelist | Louise Ross *(UK)*  
Panelist | Derek Yach *(South Africa)*  
Panelist | Martin Cullip *(UK)*  

### 17:45 - 19:30
**Networking Reception: Drinks and canapes**  
**FOYER**
11:30 - 13:00 Film Festival, Part 1: Discovering “The Missing Link”

<table>
<thead>
<tr>
<th>Chair</th>
<th>Aaron Biebert (USA)</th>
</tr>
</thead>
<tbody>
<tr>
<td>“Global Confusion” (8 minutes)</td>
<td>Directed by Aaron Biebert</td>
</tr>
<tr>
<td>“Smoking Culture in Greece, South Africa, &amp; India” (8 minutes)*</td>
<td>Directed by Aaron Biebert</td>
</tr>
<tr>
<td>“Life in Smoke - Una Vita in Fumo” (8 minutes)</td>
<td>Directed by Gianluca Fratellini (Italy)</td>
</tr>
<tr>
<td>“Missing Link in the United Kingdom &amp; Japan” (5 mins)*</td>
<td>Directed by Aaron Biebert</td>
</tr>
<tr>
<td>“The Switch” (6 minutes)</td>
<td>Produced by NCSCT (UK)</td>
</tr>
</tbody>
</table>

**Short break**

| “Introduction to Vaping for Smokers” (14 minutes) | Produced by NCSCT (UK) |
| “E-cigarette Safety: The Facts Explained” (14 minutes) | Produced by NCSCT (UK) |
| “Top Tips for Safer Vaping” (6 minutes) | Produced by NCSCT (UK) |

13:00 - 14:00 Lunch Break & Science Posters

**Poster session 1 - meet the poster presenters**

14:00 - 15:30 Film Festival, Part 2: The Battle for Truth

<table>
<thead>
<tr>
<th>Chair</th>
<th>Aaron Biebert (USA)</th>
</tr>
</thead>
<tbody>
<tr>
<td>“The Vaping (Not) Dead” (8 minutes)*</td>
<td>Directed by Dominique Aubert (France)</td>
</tr>
<tr>
<td>“Stupid Sheep in Pasadena” (3 minutes)</td>
<td>Produced by the American Vaping Association (USA)</td>
</tr>
<tr>
<td>“Give Us a Chance” (4 minutes)*</td>
<td>Directed by Asa Saligupta (Thailand)</td>
</tr>
<tr>
<td>“The Nicotine Wars: Vaping and Mental Illness” (8 minutes)*</td>
<td>Directed by Natisha Sands (Australia)</td>
</tr>
<tr>
<td>“Vaping Saves Lives: Desperate to Determined” (5 minutes)</td>
<td>Directed by Clayton Moneymaker (USA)</td>
</tr>
<tr>
<td>“Knowing My Granddaughter” (2 minutes)</td>
<td>Produced by the American Vaping Association (USA)</td>
</tr>
<tr>
<td>“A Visit to Israel &amp; Malawi” (5 minutes)*</td>
<td>Directed by Aaron Biebert</td>
</tr>
</tbody>
</table>

**Short break**

| “Persecuted” (16 minutes) | Directed by Robert Bernarius (Hungary) |
| “Clouds” (5 minutes)* | Directed by Cai Tinsley (UK) |
| “Passive Vaping: A Guide for Parrots” (5 minutes) | Produced by NCSCT (UK) |
| “A Hopeful Future” (3 minutes)* | Directed by Aaron Biebert (France) |
| “A Plan for Our People” (3 minutes)* | Directed by Aaron Biebert (New Zealand) |

* Denotes World Premiere
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:30 - 11:00</td>
<td>Plenary 2: Science and the new understandings of nicotine</td>
<td>BALLROOM CD</td>
</tr>
<tr>
<td>Chair</td>
<td>David Sweanor (Canada)</td>
<td></td>
</tr>
<tr>
<td>Presenter</td>
<td>Caitlin Notley (UK) - Nicotine in everyday life – from addiction to recreation</td>
<td></td>
</tr>
<tr>
<td>Presenter</td>
<td>Paul Newhouse (USA) - Nicotine therapeutics: therapeutic aspects of nicotinic stimulation for brain disorders</td>
<td></td>
</tr>
<tr>
<td>Presenter</td>
<td>Martin Jarvis (UK) - Michael Russell’s take on nicotine, smoking and harm reduction: how well does it stand up, 25 years on?</td>
<td></td>
</tr>
<tr>
<td>Presenter</td>
<td>Ed Stephens (UK) - The role of emissions in the debate on health effects across the spectrum of nicotine delivery</td>
<td></td>
</tr>
<tr>
<td>11:00 - 11:30</td>
<td>Break</td>
<td>FOYER</td>
</tr>
<tr>
<td>11:30 - 13:00</td>
<td>Plenary 3: Neglected issues – and those who are left behind</td>
<td>BALLROOM CD</td>
</tr>
<tr>
<td>Chair</td>
<td>Caitlin Notley (UK)</td>
<td></td>
</tr>
<tr>
<td>Presenter</td>
<td>Rajesh Sharan (India) - India and tobacco – rethinking the issues and the solutions</td>
<td></td>
</tr>
<tr>
<td>Presenter</td>
<td>Helen Redmond (USA) - The Switch: the challenges for active drug users to switch from smoking to vaping</td>
<td></td>
</tr>
<tr>
<td>Presenter</td>
<td>Annie Kleykamp (USA) - Rethinking nicotine across the lifespan: what about the older smoker?</td>
<td></td>
</tr>
<tr>
<td>Presenter</td>
<td>Frances Thirlway (UK) - Poor smokers and harm reduction: why smoking still makes sense</td>
<td></td>
</tr>
<tr>
<td>13:00 - 14:00</td>
<td>Lunch Break &amp; Science Posters</td>
<td>FOYER</td>
</tr>
<tr>
<td></td>
<td>Poster session 2 - meet the poster presenters</td>
<td></td>
</tr>
<tr>
<td>14:00 - 15:30</td>
<td>Panel Debate: Rethinking Nicotine: Where to next?</td>
<td>BALLROOM CD</td>
</tr>
<tr>
<td>Hosts</td>
<td>Clive Bates (UK) &amp; Sharon Cox (UK)</td>
<td></td>
</tr>
<tr>
<td>Panelist</td>
<td>Greg Wilson (USA)</td>
<td></td>
</tr>
<tr>
<td>Panelist</td>
<td>Kgosi Letlape (South Africa)</td>
<td></td>
</tr>
<tr>
<td>Panelist</td>
<td>Jeannie Cameron (UK)</td>
<td></td>
</tr>
<tr>
<td>Panelist</td>
<td>Konstantinos Farsalinos (Greece)</td>
<td></td>
</tr>
<tr>
<td>15:30 - 15:45</td>
<td>Break</td>
<td>FOYER</td>
</tr>
<tr>
<td>15:45 - 16:30</td>
<td>Closing Session</td>
<td>BALLROOM CD</td>
</tr>
<tr>
<td>Chair</td>
<td>David Sweanor (Canada) - Chair of GFN</td>
<td></td>
</tr>
<tr>
<td>Rapporteurs</td>
<td>Harry Shapiro (UK) &amp; David MacKintosh (UK)</td>
<td></td>
</tr>
<tr>
<td>Film Fest Award</td>
<td>Presented by Aaron Biebert (USA)</td>
<td></td>
</tr>
<tr>
<td>Three reflections on the conference</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Presenter</td>
<td>Alex Wodak (Australia)</td>
<td></td>
</tr>
<tr>
<td>Presenter</td>
<td>Andy Morrison (UK)</td>
<td></td>
</tr>
<tr>
<td>Presenter</td>
<td>Cynthia Cabrera (USA)</td>
<td></td>
</tr>
</tbody>
</table>
Gregory Conley is the president of the American Vaping Association (AVA), a nonprofit organization that champions regulatory policies including national umbrella agencies and social enterprises aimed at improving practice and approach and influencing social policy. He has been a prominent defender of tobacco harm reduction tools, such as heat-not-burn cigarettes. Karolien Adriaens obtained her Master’s degree in Clinical Psychology in 2014, conducting one of the first RCT’s concerning electronic cigarettes. Currently, she is pursuing a Ph.D. in Psychology at the Centre for the Psychology of Learning and Experimental Psychopathology at the KU Leuven. Her main research interests are tobacco harm reduction, e-cigarettes, and newly developed harm reduction tools, such as heat-not-burn cigarettes. Karolien investigates the effect of electronic cigarettes as a harm reduction tool in different groups of current smokers: first time e-cigarette users, dual users and smokers who visit a tobacco counselor to quit smoking. CEN TC 437 on electronic cigarettes and e-liquids. He has worked for a range of leading vapour companies in the EU, US and China.

Clive Bates is Managing Director of Beckett Associates, a management consultancy that helps vaping companies survive and grow while navigating political and regulatory risk around the world. Before starting his firm, he spent nearly three years as Head of Public Policy for ECIGA, where he was responsible for industry-level political advocacy during the procedure that led to the passage of the TPD. He has also been instrumental in TPD’s implementation, is an expert in compliance with its requirements and was at the centre of negotiations that led to the formation of CEN TC 437 on electronic cigarettes and e-liquids. He has worked for a range of leading vapour companies in the EU, US and China.

Peter Beckett is Managing Director of Beckett Associates, a management consultancy that helps vaping companies survive and grow while navigating political and regulatory risk around the world. Before starting his firm, he spent nearly three years as Head of Public Policy for ECIGA, where he was responsible for industry-level political advocacy during the procedure that led to the passage of the TPD. He has also been instrumental in TPD’s implementation, is an expert in compliance with its requirements and was at the centre of negotiations that led to the formation of CEN TC 437 on electronic cigarettes and e-liquids. He has worked for a range of leading vapour companies in the EU, US and China.

Aaron Beibert, Director & Executive Producer of “A Billion Lives”, won top honors for his documentary, including the Supreme Jury Prize and Best Director at the July 2016 Melbourne Documentary Film Festival in Australia, a Remi Award at the Worldfest International Film Festival in Houston, and the Dorn Award from the GFN. Aaron’s production company, Attention Era Media, is one of the most successful, video production and digital social media companies in the Midwest. Producing commercials and short films for clients such as Applebee’s, IndyCar, the NCAA, the Make-A-Wish Foundation, Attention Era balances the firm’s client load between for-profit and passion projects.

Veronica is in the final year of her PhD. She has worked in the nicotine and tobacco research area for over five years and her studies focus on smoking and social disadvantage. Her work is embedded with high consumer engagement and aims to improve delivery of new and enhanced evidence-based cessation strategies for disadvantaged smokers.

Thomas Brandon, Ph.D. is Chair of the Department of Health Outcomes and Behavior at the H. Lee Moffitt Cancer Center and Research Institute, in Tampa, Florida, where he also directs the Tobacco Research and Intervention Program. He has over 30 years of experience studying factors that maintain tobacco dependence and developing novel, theory-based tobacco-cessation and relapse-prevention interventions. He co-authored Annual Review articles on smoking motivation and relapse/relapse prevention and is the former journal editor of Psychology of Addictive Behaviors. Recently, Dr. Brandon has expanded his research to study the addiction mechanisms and potential clinical utility of e-cigarettes.

Cynthia Cabrera is a seasoned expert in the vapor space, involved in the vapor industry since 2011. As Founder and president of The Rating Group, Cynthia and her team provide business-consulting services including compliance, manufacturing operations, restructuring, government affairs, and product development including new product development and distribution. She is a frequent speaker on trends, product evolvement, distribution channels, and regulatory and legislative issues. Cynthia has presented for TMA, GTNF, GFN, FDII, RRF, ECG USA, the Morven Dialogues and a wide variety of vapor shows and exhibits.

Oscar M. Camacho is the scientific data and statistics manager at British American Tobacco (BAT). A trained Statistician and Bioinformatician with a Masters in biometrics and a Masters in applied bioinformatics with a background in teaching and the financial sector, he joined BAT’s research and development function in 2010 as a technical specialist in statistics. He leads a team providing R&D with support in statistics, data management, bioinformatics, and mathematical modelling. A key area of his work is contributing to the reduced-risk substantiation work streams ensuring appropriate study design, sound data analysis techniques, and reporting are applied throughout studies’ life cycles.

Jeannie Cameron is founder and managing director of JCIC International Ltd, a UK based strategic advocacy consultancy specializing in tobacco harm reduction, anti-illicit trade and supply-chain security. For 10 years until 2011 Jeannie was responsible for worldwide advice on all aspects of the FCTC and the FCTC Protocol, including leading delegations to Geneva negotiations, and is a known FCTC expert. In 2007 Jeannie received a distinction for her Masters in Law (LLM) dissertation: Emerging International Public Health Issues – Human Rights, Harm Reduction and the FCTC, and continues to advocate about the legal basis on which the FCTC requires Parties to implement harm reduction strategies. 

Martin Cawley joined the Big Lottery Fund in September 2016 as Director for Scotland following a successful period as chief executive of Turning Point Scotland. Martin has worked in practitioner, management and leadership positions in both the statutory and voluntary sectors for over 34 years. Martin has extensive experience of developing and managing person centered services designed to help people achieve full and active citizenship. Over the years he has also been a board member of a number of smaller organisations including national umbrella agencies and social enterprises aimed at improving practice and approach and influencing social policy.

Gregory Conley is the president of the American Vaping Association (AVA), a nonprofit organization that champions regulatory policies towards vapor products designed to maximize the effectiveness of vaping for quitting smoking. He is one of the most prominent defenders of vaping in the United States and has appeared on CNN, Fox News, and MSNBC. Mr. Conley is also an attorney and a consultant on vaping legislative and regulatory issues. He began working on vaping issues in 2010 after quitting smoking with a vapor product while in law school. He served as the pro bono legislative director for the Consumer Advocates for Smoke-Free Alternatives Association from 2011 to 2014.

Aaron Beibert, Director & Executive Producer of “A Billion Lives”, won top honors for his documentary, including the Supreme Jury Prize and Best Director at the July 2016 Melbourne Documentary Film Festival in Australia, a Remi Award at the Worldfest International Film Festival in Houston, and the Dorn Award from the GFN. Aaron’s production company, Attention Era Media, is one of the most successful, video production and digital social media companies in the Midwest. Producing commercials and short films for clients such as Applebee’s, IndyCar, the NCAA, the Make-A-Wish Foundation, Attention Era balances the firm’s client load between for-profit and passion projects.

Veronica is in the final year of her PhD. She has worked in the nicotine and tobacco research area for over five years and her studies focus on smoking and social disadvantage. Her work is embedded with high consumer engagement and aims to improve delivery of new and enhanced evidence-based cessation strategies for disadvantaged smokers.

Thomas Brandon, Ph.D. is Chair of the Department of Health Outcomes and Behavior at the H. Lee Moffitt Cancer Center and Research Institute, in Tampa, Florida, where he also directs the Tobacco Research and Intervention Program. He has over 30 years of experience studying factors that maintain tobacco dependence and developing novel, theory-based tobacco-cessation and relapse-prevention interventions. He co-authored Annual Review articles on smoking motivation and relapse/relapse prevention and is the former journal editor of Psychology of Addictive Behaviors. Recently, Dr. Brandon has expanded his research to study the addiction mechanisms and potential clinical utility of e-cigarettes.

Cynthia Cabrera is a seasoned expert in the vapor space, involved in the vapor industry since 2011. As Founder and president of The Rating Group, Cynthia and her team provide business-consulting services including compliance, manufacturing operations, restructuring, government affairs, and product development including new product development and distribution. She is a frequent speaker on trends, product evolvement, distribution channels, and regulatory and legislative issues. Cynthia has presented for TMA, GTNF, GFN, FDII, RRF, ECG USA, the Morven Dialogues and a wide variety of vapor shows and exhibits.

Oscar M. Camacho is the scientific data and statistics manager at British American Tobacco (BAT). A trained Statistician and Bioinformatician with a Masters in biometrics and a Masters in applied bioinformatics with a background in teaching and the financial sector, he joined BAT’s research and development function in 2010 as a technical specialist in statistics. He leads a team providing R&D with support in statistics, data management, bioinformatics, and mathematical modelling. A key area of his work is contributing to the reduced-risk substantiation work streams ensuring appropriate study design, sound data analysis techniques, and reporting are applied throughout studies’ life cycles.

Jeannie Cameron is founder and managing director of JCIC International Ltd, a UK based strategic advocacy consultancy specializing in tobacco harm reduction, anti-illicit trade and supply-chain security. For 10 years until 2011 Jeannie was responsible for worldwide advice on all aspects of the FCTC and the FCTC Protocol, including leading delegations to Geneva negotiations, and is a known FCTC expert. In 2007 Jeannie received a distinction for her Masters in Law (LLM) dissertation: Emerging International Public Health Issues – Human Rights, Harm Reduction and the FCTC, and continues to advocate about the legal basis on which the FCTC requires Parties to implement harm reduction strategies. 

Martin Cawley joined the Big Lottery Fund in September 2016 as Director for Scotland following a successful period as chief executive of Turning Point Scotland. Martin has worked in practitioner, management and leadership positions in both the statutory and voluntary sectors for over 34 years. Martin has extensive experience of developing and managing person centered services designed to help people achieve full and active citizenship. Over the years he has also been a board member of a number of smaller organisations including national umbrella agencies and social enterprises aimed at improving practice and approach and influencing social policy.

Gregory Conley is the president of the American Vaping Association (AVA), a nonprofit organization that champions regulatory policies towards vapor products designed to maximize the effectiveness of vaping for quitting smoking. He is one of the most prominent defenders of vaping in the United States and has appeared on CNN, Fox News, and MSNBC. Mr. Conley is also an attorney and a consultant on vaping legislative and regulatory issues. He began working on vaping issues in 2010 after quitting smoking with a vapor product while in law school. He served as the pro bono legislative director for the Consumer Advocates for Smoke-Free Alternatives Association from 2011 to 2014.
**SHARON COX, UK**

Dr Sharon Cox has over ten years’ experience working in the drug and alcohol field, including working at front-line services with some of the UK’s most deprived communities. She has a special interest in harm reduction and the use of translational methodologies in vulnerable and marginalised groups. She currently works as a Research Fellow at London South Bank University’s Centre for Addictive Behaviours Research. Her current research is focused on e-cigarette puffing patterns associated with high and low nicotine e-liquid strength, smoking and alcohol consumption within disadvantaged groups and the impact of health warning labels on reduced risk products.

**MARTIN CULLIP, UK**

Martin Cullip is a transport company director who uses e-cigarettes and other reduced risk nicotine products and has seen a positive shift in recent years of his staff members quitting or reducing smoking by vaporising instead. He is a passionate consumer advocate of all forms of tobacco harm reduction and is an Associate of the NNA UK as well as an adviser to the Freedom Association’s Freedom to Vape campaign. He has a keen interest in the rapidly-evolving nicotine market, in particular the politics surrounding it, and has taken part in consumer, industry and political events on the subject from Bournemouth to Brussels and beyond.

**AMY FAIRCHILD, USA**

Amy Fairchild is a historian who works at the intersection of ethics and policy. Her work in harm reduction, privacy and surveillance, and immigration and border control is fundamentally concerned with the politics of public health and the tensions between ethics and evidence. In addition to her publications in leading journals, Fairchild is the author of two books: *Science at the Borders: Disease and the Making of the Modern Industrial Labor Force and Searching Eyes: Privacy and Disease Surveillance in America*. Her current work includes a cross-national project on harm reduction and the ethics and politics of e-cigarettes.

**HANNAH FARRIMOND, UK**

Dr Hannah Farrimond is a Senior Lecturer in Medical Sociology in the Department of Sociology, Philosophy and Anthropology at the University of Exeter, UK. Her PhD from UCL addressed the social identity of smokers in diverse socio-economic groups (2007). Her current work focuses more broadly on legal addictions, particularly as they relate to new technologies. She is currently PI on a CRUK funded case study examining how English Stop Smoking Services have responded to e-cigarettes. Her recent papers on e-cigarettes in journals such as Addiction and the UJDP have focused on vaping, regulation, disadvantage, identity and stigma as they relate to public health policy.

**KONSTANTINOS E. FARSALINOS, GREECE**

Konstantinos E. Farsalinos, M.D., is a research fellow at the Onassis Cardiac Surgery Center in Athens, Greece, at the Department of Pharmacy, University of Patras, Greece, and at the National School of Public Health-Greece. He has been conducting laboratory and clinical research on e-cigarettes as a principal investigator since 2011. Examples of his work include the first study on the cytotoxic effects of e-cigarette vapor on cultured cells and the immediate effects of e-cigarette use on cardiac function and coronary circulation. As of early 2018, he has published more than 60 studies and articles in international peer-reviewed scientific journals.

**DANIEL FRINGS, UK**

Daniel is an Associate Professor in Psychology, with a particular focus on habitual behaviours. He has authored over 40 publications, including journal articles, book chapters, a popular press psychology book and a concise overview of social psychology aimed at students. Daniel has received funding from Cancer Research UK, the Economic Social Research Council, British Academy, Alcohol Research UK, the European Regional Development Fund and both commercial and third sector partners. He is currently leading a clinical RCT comparing two stop smoking treatments (ISRCTN23584477). He is an Associate Editor of the Journal of Applied Social Psychology.

**JUDY GIBSON, UK**

Judy Gibson is the CEO of The International Network of Nicotine Consumer Organisations; a Civil Society organisation currently representing 32 consumer advocate organisations in 27 countries in 5 continents. Its aim is to reduce the harm posed by combustible and toxic forms of tobacco by advocating for the global adoption of harm reduction, and its belief is that the public have a right to be given honest information and to choose legally accessible, affordable, alternative and safer forms of nicotine. Using early iterations of e-Liquid vapourisers since 2012, she became an ex-smoker in 2015. She is quite oldish, passionate about politics, reading Sibelius, THR and red wine.

**JOE GITCHELL, USA**

Joe Gitchell provides strategic counsel to clients across a wide range of health policy, regulatory, and marketing and communications challenges. With a focus on client service, Joe leads efforts supporting regulatory approvals, conducting public policy analysis, developing communications approaches, devising, refining and defending claims, and providing input on strategic market opportunities. He has counseled clients navigating health policy and communications challenges in the US, Europe, Latin America, Asia and the Middle East. Joe serves as the president of Pinney Associates where he provides consulting services on smoking cessation and tobacco harm minimization.

**MAREWA GLOVER, NEW ZEALAND**

Professor Marewa Glover has worked on reducing smoking-related harm for over 25 years. She has worked as a policy analyst, a co-ordinator of a national tobacco control programme, cessation trainer and, for over 17 years, as a researcher. She has chaired numerous committees and organisations including End Smoking NZ, an independent NGO that lobbied for a harm reduction public health approach even before electronic cigarettes were introduced. Marewa has over 100 publications reflecting her leadership and support of numerous studies. Her primary focus has been on reducing smoking during pregnancy and reducing smoking among Māori, the indigenous people of New Zealand.

**ROBYN GOUGELET, USA**

Robyn Gouvelet works at Pinney Associates and advises on public health legislative and regulatory policy strategy for tobacco harm reduction efforts and execute on targeted efforts. Before joining Pinney Associates as an Associate in June 2015, Robyn worked for three years at Trust for America’s Health, a non-profit, non-partisan organization in Washington, D.C. dedicated to saving lives by protecting the health of every community and working to make disease prevention a national priority. In that role, Robyn helped to inform Members of Congress and their staff about state-specific prevention and public health provisions and programs created by the Affordable Care Act.

**CHRISTELLE HAZIZA, SWITZERLAND**

Christelle Haziza leads the Clinical Science group for Philip Morris International R&D, in Neuchâtel, Switzerland. She focuses her research efforts on harm reduction strategy in the context of smoking. She is accountable for the scientific strategy of PMI clinical assessment programs, conducted with smokers who have switched to the portfolio of reduced-risk products developed within the company, to demonstrate a significantly reduced risk of smoking-related diseases compared with continued smoking of cigarettes. Christelle has published numerous articles in international peer-reviewed scientific journals and holds a Ph.D. in Life Sciences.
SPEAKERS & CHAIRS

RICHARD HOLLIDAY, UK
Richard Holliday is a Specialty Registrar (StR) in Restorative Dentistry and NIHR Doctoral Research Fellow at Newcastle University. UK. Richard’s research interests are focused on periodontal diseases, particularly risk factors, and he is currently completing his PhD on ‘e-cigarettes as a smoking cessation or harm reduction tool for patients with periodontitis’. The main body of this work is a feasibility randomised controlled trial of 80 smokers with periodontitis. Additional projects include surveys of tobacco education in UK dental schools, surveys of practitioner opinions and in vitro analysis.

SARAH JAKES, UK
Since leaving school, ‘a very long time ago’, Sarah has worked in the shipping industry, the foreign exchange market and now runs her own business in property management. A smoker for some 35 years, Sarah switched to vaping in 2013, only to find that the choice of this safer alternative for smokers was under threat from excessive and ill-founded regulation. Having joined forces with other consumers in the battle against over-regulation in the EU parliament, Sarah is convinced that a better understanding of e-cigarettes and other harm reduced products among key influencers and decision makers is required if these products are ever to reach their full potential for public health gains.

MARTIN JARVIS, UK
Martin Jarvis is Emeritus Professor of Health Psychology at the Department of Epidemiology and Public Health, University College London. Over the past 35 years he has researched and published widely on tobacco smoking, with special interests in the role of nicotine, social and family influences on smoking, smoking cessation methods and passive smoking. He is a trustee of ASH, and was Deputy Chair of the UK government’s Scientific Committee on Tobacco and Health and Specialist Adviser to the House of Commons Health Committee’s inquiries into tobacco and health and into smoking in public places.

CECILIA KINDSTRAND-ISAKSSON, SWEDEN
Cecilia Kindstrand is Director of Public Affairs for Swedish Match, a tobacco company with tobacco harm reduction at the core of its business. She is based in Brussels and has worked extensively with the revision of the EU’s Tobacco Products Directive, a legislation banning the ‘proof of concept’ of tobacco harm reduction in 27 of the 28 Member States. The vision of Swedish Match is A World Without Cigarettes.

BETHEA (ANNIE) KLEYKAMP, USA
Dr Bethea (Annie) Kleykamp is a Scientist at the health-care consulting firm, Pinney Associates. She earned her PhD at Virginia Commonwealth University and completed postdoctoral training at the Johns Hopkins University School of Medicine and the Intramural Program of the National Institute on Drug Abuse. Her research focused on the cognitive effects of a variety of psychoactive drugs (e.g., nicotine, alcohol, methadone). Prior to joining Pinney Associates in 2014, she worked at the health technology assessment company Hayes, Inc., where she wrote systematic reviews that informed healthcare decisions for government, health insurance, and healthcare provider clients.

JOE KOSTERICH, AUSTRALIA
Doctor, speaker, author; media presenter and health industry consultant, Dr. Joe Kosterich wants you to be healthy and get the most out of life. Joe writes for numerous medical and mainstream publications and is also a regular on radio and television. He is often called to give opinions in medico legal cases and he is also an adjunct professor (teaching) at the UWA. He is on the editorial advisory panel of Medical Forum Magazine and Reed Medical Conferences. Dr. Joe maintains a website and blog with health information and commentary. He self-published two books: Dr Joe’s DIY Health and 60 Minutes To Better Health.

PATRICIA KOVAČEVIĆ, USA
Patricia I. Kovacević, Esq. is the General Counsel and Chief Compliance Officer of Nicopure Labs LLC. With extensive international industry experience, she held senior legal and compliance positions at, among other, Philip Morris International and Lorillard. Prior to joining Lorillard she was a partner at Patton Boggs. Her expertise includes global e-cigarette and tobacco regulation, compliance and all regulatory aspects of media communications, corporate affairs, criminal investigations, FDA, trade sanctions, privacy & product development. She holds a Juris Doctor degree from Columbia Law School, NY, and has completed the Harvard Business School’s ‘Corporate Leader’ management course.

GRZEGORZ KRÓL, POLAND
Grzegorz Krol, Ph.D - social psychologist, assistant professor at the Faculty of Management, University of Warsaw. Author of monographs and chapters on data analysis, and several of papers in peer-reviewed journals. Developer of data-centric IT solutions for e-learning, event management, and online acquisition of quantitative information. Between 2003 and 2011 managed European projects, and organised several international conferences in the area of drugs & harm reduction. Since 2012 his focus shifted towards nicotine harm reduction.

HIROYA KUMAMARU, JAPAN
Hiroya Kumamaru, M.D. PhD, is Vice Director of the AOI Universal Hospital since 2013. He graduated from Medical School, Keio University, Japan, in 1980. Trained in General Surgery & Cardiovascular Surgery at Keio University Hospital & at other Affiliated Hospitals 1980 to 1988. Clinical Research Fellowship in the Dept. of Cardiovascular Surgery, St. Vincent Medical Center in LA. Surgical Residency in Cardiovascular Surgery of Centre Cardio-Thoracique de Monaco Staff Surgeon of Cardiovascular Surgery in affiliated Hospitals till 2008. Cardiovascular Medical Director in Pfizer Japan from 1996 to 2005. Private practice in Tokyo Metropolitan area 2008 to 2013 focusing on smoking cessation.

JACQUES LE HOUEZEC, FRANCE
Trained neuroscientist in Paris (PhD in 1988) who spent 2 years as a post-doctoral fellow in Clinical Pharmacology & Experimental Therapeutics at the University of California. After 6 years of research in La Salpêtrière Hospital, (Paris), and teaching at Paris V and Paris VII Universities, he became a freelance consultant for the pharmaceutical industry and the public sector (training smoking cessation specialists, and writing scientific digests for them). He is a Charter Member of SRNT and was part of the core group who founded SRNT Europe. He is also an Honorary Lecturer at the UK Centre for Tobacco Control Studies, University of Nottingham, UK, and manager of www.treattobacco.net.

KGOSI LETLAPE, SOUTH AFRICA
David Levy has a PhD in Economics from UCLA (USA), and is currently a Professor of Oncology at Georgetown University. He has published over 250 articles, including in the American Economic Review, the BMJ, the AIPH, the JAMA, Lancet, Tobacco Control, and PLOS Medicine. He has been principal investigator of grants from the CDC, WHO, the National Cancer Institute, and Bloomberg/Gates Foundation. Dr. Levy is currently overseeing the design and development of the SimSmoke tobacco policy simulation model, for which he has developed models for over 40 countries covering 85% of the world population. He is now developing models of smokeless tobacco and e-cigarette use.

Karl Erik Lund is Senior Researcher at the Norwegian Institute of Public Health. He has been involved in tobacco control work since the mid 1980s, working at the Norwegian Council on Tobacco or Health (Deputy Leader), the Norwegian Cancer Society (Director for Department of Cancer Prevention) and the Norwegian Institute for Alcohol and Drug Research (Research Director). Dr. Lund received the Norwegian Medical Association’s Award in preventive medicine in 2000. He has been Associate Editor in the scientific journal Nicotine & Tobacco Research since 2011 and Senior Associate Editor of Tobacco Regulatory Science since 2015.

David Mackintosh is the Head of Community Safety for the City of London, and has also been the Policy Adviser/ Director to the London Drug and Alcohol Policy Forum (LDAFF) since 2001. He has been involved in a number of innovative campaigns around issues including drug driving, substance misuse in the workplace and improving awareness around drug safety in clubs and pubs. For the last eight years he has also been seconded to the Greater London Authority to provide advice around substance use issues and health inequalities. Prior to this post David worked for the United Kingdom Anti-Drug Co-ordination Unit, following on from some 8 years in the Department for Education and Skills.

Colin Mendelsohn is an Associate Professor at the School of Public Health and Community Medicine at the University of New South Wales, Sydney, Australia. He is a medical practitioner and tobacco treatment specialist working in private practice and is Chairman of the Australian Tobacco Harm Reduction Association. He is actively involved in raising awareness of the public health benefits of tobacco harm reduction and advocating for the legalisation of vaping in Australia. Colin is a member of the committee that develops the Australian national smoking cessation guidelines and is past Vice President of the Australian Association of Smoking Cessation Professionals.

Dr. James Murphy holds a PhD in polymer chemistry and joined us in 2005 after postdoctoral research at the Nara Institute of Science & Technology in Japan developing novel polymer-based drug delivery systems. He has held a variety of roles in R&D including leading the development and assessment of a Reduced Toxicant Prototype cigarette, as well as, development and commercialisation of Vype e-cigarettes. He now heads up our Reduced Risk Substantiation unit, overseeing all of our pre-clinical and clinical research programs. His group is working on research methodologies to substantiate the reduced-risk potential of next-generation products.

Paul Newhouse, M.D. holds the Jim Turner Chair in Cognitive Disorders at Vanderbilt University School of Medicine and is Professor of Psychiatry, Pharmacology, and Medicine. He is Director of the Vanderbilt Center for Cognitive Medicine (VCCM) in the Department of Psychiatry and Behavioral Sciences at Vanderbilt University Medical Center. He is also a physician-scientist at the Veterans Affairs Tennessee Valley Health Systems Geriatric Research, Education, and Clinical Center (GRECC). He is an Army veteran, directed a research laboratory for the Walter Reed Army Institute of Research, and served in Operation Desert Storm.

Dr. Notley is a Senior Lecturer in Mental Health at the Norwich Medical School, University of East Anglia (UK), and a Research Fellow of the UK Society for the Study of Addiction. She is a social scientist with extensive experience in addiction research. Her programme of research is focused on tobacco smoking relapse prevention, particularly working with vulnerable groups. Dr. Notley’s research interests in alternative nicotine delivery devices primarily explores social and culturally pertinent aspects of vaping. Her work emphasises the public health potential of vaping for smoking relapse prevention, taking a ‘real world’ perspective to highlight the importance of user focused perspective.

Laura Leigh Oyler is the Senior Director of Policy and Advocacy for Reynolds American Inc. Services Company. Her work focuses on tobacco harm reduction policy and regulation.

Dr Sudhanshu Patwardhan is a medical doctor and an MBA with two decades of international experience in biomedical research and regulatory strategy in the pharmaceutical and tobacco industries. He has been with the British American Tobacco Group for the past thirteen years, focusing on nicotine policy, product science and KOL engagement. Sud passionately believes in the role of educating health care professionals in achieving tobacco harm reduction globally. He keenly tweets as @DocTHRNic, primarily on tobacco control challenges in LMIC. Sud lives in Hampshire, England, with his wife and two children. He is very active as a Director of the charity Art Asia, UK.

Helen Redmond, is an expert in substance use with over a decade of experience working with drug users and people with mental health problems in medical and mental health settings and in community supportive housing. Her current focus is on helping vulnerable and stigmatized populations transition to e-cigarettes. She is an independent journalist and writes about vaping, mental health and drug policy. Helen is a filmmaker and made a short documentary about people with serious mental health problems and smoking. She provides tobacco harm reduction trainings via her consulting firm, Nicotine Harm Reduction Consultants. She is adjunct faculty at New York University.

Louise Ross was the leader of the Leicester City Stop Smoking Service. Louise finished a very happy and long working life in learning disabilities to work in tobacco control and smoking cessation, and has been delighted to discover a second career that has been even more satisfying than the first. Initially sceptical about e-cigs, she has become a vocal advocate for their use as a harm reduction method, principally because she has listened to people who have used them to stop smoking, and has been utterly convinced by their sincerity. Louise is an associate of the NNA UK, a charity committed to improving public health through a greater understanding of risk-reduced nicotine products.
Frances is bilingual in French and hopes to extend her research to the ex-mining areas of Northern France.

His research has been supported by UK research councils, the NIH, the EU and medical charities.

He is Honorary Professor at the London School of Hygiene and Tropical Medicine, and Emeritus Professor at Imperial College London.

Here are some works by Dr. Sarkar:
- "Chemical Composition of E-Cigarettes and Its Impact on Public Health" in Tobacco Control.

Rajesh is a Molecular Biologist and Biochemist by training with over 3 decades of research experience in the field of betel (Areca) nut & chemical induced carcinogenesis, and molecular mechanisms of radiation induced damage to DNA & its repair with expertise in biomarker discovery for cancer and radiation damage assessment for their clinical applications.

His research has been supported by UK research councils, the NIH, the EU and medical charities.

Robert A. Sussman, Mexico

Dr. Sussman is a member of INNCO. Dr. Sussman is actively advocating for an appropriate regulation of Tobacco Harm Reduction products in Mexico. As a full-time senior researcher in physics at the National University of Mexico (UNAM), he directs and supervises the effort to spread scientific information on these products, as well as advising consumers on how to counter the misinformation and prejudice about them that is rampant throughout Latin America.

He has over 220 scientific publications and several books.

His research has been supported by UK research councils, the NIH, the EU and medical charities.

SPEAKERS & CHAIRS

MOHAMADI SARKAR, USA

Mohamadi Sarkar, M.Pharm., Ph.D., FCCP serves as Senior Principal Research Scientist for Altria Client Services in Richmond, Va. He has held this position since August 2002. In his current role Dr. Sarkar provides strategic direction for developing the scientific evidence on reduced risk products made by Altria Group’s tobacco companies. He has authored more than 100 scientific peer-reviewed publications and presentations at scientific meetings. Dr. Sarkar also has participated in several invited seminar presentations and authored a variety of scientific book chapters related to his areas of expertise.

HARRY SHAPIRO, UK

Harry Shapiro had worked in the UK drugs field since 1979 involved in communications, information, writing, editing, public speaking and lecturing. From 2000-2015, he was Director of Communications for DrugScope and was their main media spokesperson. He is now Director of DrugWise, an online drug information service. He entered the world of tobacco harm reduction in 2016 as rapporteur for the GHN conference, began a weekly blog for Nicotine Science and Policy Digest in January 2017 and is the lead author and editor of the first Global State of Tobacco Harm Reduction report due to be published in October.

RAJESH SHARAN, INDIA

Rajesh N. Sharan, Ph. D., is a Professor at the Department of Biochemistry and Director of Design Innovation Center at the North-Eastern Hill University, Shillong (India). Rajesh is a Molecular Biologist and Biochemist by training with over 3 decades of research experience in the field of betel (Areca) nut & chemical induced carcinogenesis, and molecular mechanisms of radiation induced damage to DNA & its repair with expertise in biomarker discovery for cancer and radiation damage assessment for their clinical applications. Rajesh is a former President of the Indian Society for Radiation Biology and currently a member of the CRP of IAEA (Vienna). He has authored over 105 research publications & books.

PAWEŁ JULIUSZ SKUTECKI, POLAND

Paweł Julisz Skutecki, Polish MP, politician and journalist, member of the Sejm of the 8th term. Paweł graduated in Polish Philology at the Academy of Bydgoszcz and he studied philosophy at the University of Warsaw as well. During the parliamentary elections of 2015, he was a candidate for the Sejm in the Bydgoszcz’s constituency and he got first place over the voters’ electoral committee list organized by Mr. Paweł Kukiz. He is a member of the Health Committee in the Polish Parliament.

KARL SNAEBJORNSSON, ICELAND

Karl is a doctor specialising in family medicine, and has consultancy jobs as a doctor in Sweden over the last decade, and also in Iceland and Norway. His wife specialised in diagnosing high functioning autism, ASD/HFF/Aasperger’s especially in girls. A father of four, and grandfather of 10 kids (yet). Over the past few years, Karl has been promoting several harmless alternatives to smoking including vaping and snus in Iceland, by writing articles, taking part in TV and radio interviews, and more. Iceland has had a success story because of the increase in prevalence of snus and vaping, and the collapse of cigarette sales and use.

ED STEPHENS, UK

Ed Stephens is Senior Research Fellow in the School of Earth & Environmental Sciences at the University of St Andrews (Scotland, UK). He has held visiting positions in France (Toulouse) and Australia (ANU). His training is in geochemistry with a current interest in modelling environmental pathways of toxicants and carcinogens. This began with modelling the controls on valence speciation of metals in tobacco and more recently has focused on chemical aspects of emissions in e-cigarettes and other forms of nicotine delivery. His research has been supported by UK research councils, the NIH, the EU and medical charities.

GERRY STIMSON, UK

Professor Gerry Stimson is a public health social scientist, with over 40 years’ experience of research and advocacy. He was one of the founders of drugs harm reduction in the 1980s and helped develop and evaluate harm reduction in the UK as a response to HIV/AIDS. He has advised the UK Government, World Health Organization, UNAIDS, the UNODC, World Bank and numerous governments on issues relating to drugs, HIV infection and AIDS, and alcohol. He has published over 220 scientific publications and several books. He is Honorary Professor at the London School of Hygiene and Tropical Medicine, and Emeritus Professor at Imperial College London.

ROBERTO A SUSSMAN, MEXICO

Dr Roberto A Sussman is the founder and Director of Pro-Vapeo Mexico, an association representing Mexican consumers of non-combustible nicotine products and is a member of INNCO. Dr Sussman is actively advocating for an appropriate regulation of Tobacco Harm Reduction products in Mexico. As a full-time senior researcher in physics at the National University of Mexico (UNAM), he directs and supervises the effort to spread scientific information on these products, as well as advising consumers on how to counter the misinformation and prejudice about them that is rampant throughout Latin America.

NANCY SUTTHOFF, NEW ZEALAND

Nancy Sutthoff is the Co-founder and Co-Director of Aotearoa Vapers Community Advocacy (AVCA) in New Zealand. Nancy has a diverse background with degrees in Police Sciences (A.A.S) and Sociology (B.A), and she has always, in one way or another, been involved in investigative and advocacy roles, from business analysis of corporate IT systems, to research administration at SUNY Stony Brook (New York, USA), to local government relations for the West Boca Community Council (Florida, USA), to youth health and education advocacy (New Zealand).

DAVID SWEANOR, CANADA

David Sweanor is chair of the advisory board of the Centre for Health Law, Policy & Ethics, and an adjunct professor at the Faculty of Law, University of Ottawa. He has been actively involved in tobacco and health policy issues since the beginning of the 1980s and played a leading role in setting many global precedents. He has worked with numerous groups globally, including the International Union Against Cancer, the World Health Organization, the World Bank and the Pan American Health Organization. The current focus of his tobacco related work is on risk reduction strategies. He was awarded Ottawa’s Outstanding Individual Philanthropist award in 2016.

FRANCES THRILWAY, UK

Frances Thrilway is a Research Fellow at the University of York working on health, class and culture; her interest in e-cigarettes is mainly in relation to their potential to address health inequalities by increasing smoking cessation in populations with high smoking prevalence. Frances is Principal Investigator on a project funded by Cancer Research UK entitled ‘Electronic cigarettes, health inequalities and smoking cessation: a community study of take-up and market evolution in two high smoking prevalence areas of the North of England’. Frances is bilingual in French and hopes to extend her research to the mining areas of Northern France.
ALEKSEI TROFIMOV, RUSSIA
Prof. Aleksei Trofimov received M.Sc. (1988) and Ph.D. (1991) degrees in physics and mathematics from the Moscow Institute of Physics and Technology and D.Sc. (“Habilitation”) degree in chemistry (2006) from the Russian Academy of Sciences (R.A.S.). During his academic career, he held positions at the Institutes of Chemical/Biochemical Physics, R.A.S. (Moscow, Russia), as Senior Scientist and Leading Scientist, and at the University of Würzburg (Germany), as the postdoctoral fellow and the Senior Research Associate with Prof. Waldemar Adam. Currently, he holds position of Deputy Director of the Emanuel Institute of Biochemical Physics, Russian Academy of Sciences.

CARRIE WADE, USA
Carrie Wade is a senior fellow and the harm reduction policy director for the R Street Institute. She joined R Street in 2017, having previously worked as an addiction researcher at the University of Minnesota and The Scripps Research Institute in La Jolla, California, focusing on mechanisms of opioid addiction and chronic pain. She transitioned to public health where her work with the Baltimore Harm Reduction Coalition solidified her goal to promote reasonable and efficient drug policies. Carrie received her Ph.D. in pharmacology and neuroscience from the University of Minnesota, USA, and a master’s in public health from Johns Hopkins University, USA.

GREG WILSON, USA
Greg Wilson serves as a Managing Director, Regulatory Affairs, Altria Client Services. Greg works on regulatory policy, harm reduction strategies and related topics.

TANVIR WALELE, NETHERLANDS
Tan Walele is a European Registered Toxicologist with significant experience in risk assessment and risk management, in-vitro toxicity models, and clinical research. At Fontem Ventures he is responsible for a team of scientists supporting non-tobacco, next generation products and heads up their stewardship function, which includes liaising with external advisors, engagement and regulatory authorities and providing advice on and management of product testing strategies. Tan is also responsible for the compilation and provision of robust & substantive scientific information in support of products as required by regulations worldwide, to ensure their approval by government authorities.

ALEX WODAK, AUSTRALIA
Dr Alex Wodak, AM, is a retired physician who is now President of the Australian Drug Law Reform Foundation. He works full-time on drug law reform as a volunteer. Together with colleagues, he started the first needle syringe programme (1986) and the first medically supervised injecting centre (1999) in Australia when both were pre-legal. Dr Wodak was President of the International Harm Reduction Association (1996-2004). He has been interested in tobacco harm reduction since 1992 but only active in THR in recent years. Dr Wodak helped to start the National Drug and Alcohol Research Centre (1987).

JULIE WOESSNER, USA
Julie Woessner is the National Policy Director of CASAA (The Consumer Advocates for Smoke-free Alternatives Association). CASAA, a nonprofit U.S.-based public health and education NGO, advocates for people who consume, or might in the future consume, low-risk alternatives to cigarettes. CASAA engages in policy advocacy in the U.S. involving legislative and regulatory matters to protect access to low-risk products and mobilizes its 200,000+ members to do the same. Internationally, CASAA provides education about tobacco harm reduction and advocacy. Woessner holds a JD from Duke School of Law and was previously a practicing attorney.

DEREK YACH, USA
Dr. Derek Yach, a global health expert and anti-smoking advocate for more than 30 years, is the president of the Foundation for a Smoke-Free World. Throughout his career, he has supported and led smoking cessation research and policy development and has been a strong proponent of harm-reduction policies, calling for a greater emphasis on harm reduction as early as 2005. He is also a passionate advocate of health promotion and disease prevention, and is advancing his career’s work at the Foundation for a Smoke-Free World. He has authored or co-authored more than 250 peer-reviewed articles on global health.
Special Issue “Tobacco Harm Reduction”

Deadline for manuscript submissions: 31 December 2018

Tobacco Harm Reduction has been a controversial area in public health, largely due to the promotion by the tobacco industry of cigarette modifications that gave the appearance of reduced harm, without reducing health risk. This may have increased overall harm by discouraging smokers from quitting. However, there is now good evidence that switching from cigarettes to some alternate nicotine and tobacco products can reduce exposure to harmful constituents and reduce health risk. The Swedish experience with snus, a form of oral snuff manufactured to limit the formation of carcinogenic nitrosamines, is an example of an alternate tobacco product with long-term epidemiological evidence to support its much lower risk profile. Newer products, such as e-cigarettes and other vaping devices and heated tobacco products are generating substantial interest. While this is a rapidly advancing research field, the recent National Academies of Science, Engineering and Medicine Report on the Public Health Consequences of E-cigarettes has identified a number of priority areas for research to help fill some of the gaps in evidence on these alternate nicotine and tobacco products. This Special Issue of IJERPH on Tobacco Harm Reduction welcomes submissions on these priority research areas and other research that advances our understanding of the potential place of tobacco harm reduction within a comprehensive strategy to reduce the burden of smoking related disease and assists policy makers to determine what level of regulation is most appropriate.

Guest Editors
Assoc. Prof. Coral Gartner  Dr. Ratika Sharma-Kumar  Dr. Kylie Morphett

Manuscripts should be submitted online at www.mdpi.com

Author Benefits

- **Open Access** Unlimited and free access for readers
- **No Copyright Constraints** Retain copyright of your work and free use of your article
- **Impact Factor 2.101 (2016 Journal Citation Reports®)**
- **Rapid Publication** First decision provided to authors approximately 22 days after submission; acceptance to publication is undertaken in 5 days
- **Coverage by Leading Indexing Services** SCIE-Science Citation Index Expanded (Clarivate Analytics), SSCI-Social Sciences Citation Index (Clarivate Analytics), Scopus, MEDLINE (NLM), PubMed Central
- **No Space Constraints, No Extra Space or Color Charges** No restriction on the length of the papers, number of figures or colors
- **Discounts on Article Processing Charges (APC)** If you belong to an institute that participates with the MDPI Institutional Open Access Program
Society for Research on Nicotine and Tobacco (SRNT) Europe
18th Annual Conference in Munich, Germany, 6–8 September 2018

Conference theme: **Smoking and Disease**

Latest findings from the fields of pre-clinical/basic science, clinical, epidemiology/public health, and policy research concerning nicotine and tobacco

Additional sessions for German clinicians: 4. Fachtagung Tabakentwöhnung, 8.–9. September 2018

**Upcoming deadlines:**
30 June 2018 for early registration
30 June 2018 for rapid response abstracts
2 September 2018 for late registration

www.srnt-e-munich.com
CONFERENCE TEAM

Gerry Stimson, Programme Director
Bisola Obileye, Finance Director

Paddy Costall, Conference Director
Grzegorz Król, Technical Director

Ian Gregory, Media Relations Manager
Emil Pevtsov, Media Relations Assistant

Joanna Junak, Event Manager
Katarzyna Kowalczyk, Event Manager

Filip Woźniak, Technical Assistant
Vlad Radchenko, Technical Assistant

Łukasz Bieniecki, Photographer
Jon Derricott, Videographer

PROGRAMME COMMITTEES

Science
Caitlin Notley, UK - Chair
Helen Redmond, USA
Leon Kośmider, USA
Ryan Courtney, Australia
Sharon Cox, UK
Karl Lund, Norway
Konstantinos Farsalinos, Greece
Raymond Niaura, USA

Policy, Advocacy & Practice
Gerry Stimson, UK - Chair
Cynthia Cabrera, USA
Mirek Dworniczak, Poland
Gillian Golden, Ireland
Robyn Gougelet, USA
Colin Mendelsohn, Australia
Rajesh Sharan, India
Olivier Théraulaz, Switzerland

Polish Host Committee
Andrzej Sobczak, Poland
Mirek Dworniczak, Poland

Consumer Engagement
Judy Gibson, UK
Announcing the launch of the first edition of the

Global State of
Tobacco
Harm Reduction

The last decade has witnessed a dramatic proliferation in the range of alternative nicotine products such as e-cigarettes and heat-not-burn devices, alongside the use of other low risk non-combustible smokeless tobaccos, such as snus. This has been accompanied in some countries by developments and changes in the profile of manufacturers and distributors, product innovation, investment in research and development, and a market driven by product availability and consumer choice. In turn this has raised challenges for countries in terms of appropriate regulatory models.

Inspired by the Global State of Harm Reduction reports published biennially by Harm Reduction International (HRI) since 2008, the landmark Global State of Tobacco Harm Reduction (GSTHR) is the first attempt to map global, regional and national changes in the availability and use of alternative nicotine products and the regulatory response to these products.

The main product is a biennial report on tobacco harm reduction, with the first issue to be published in October 2018. The report is being written by Harry Shapiro, an established author and commentator on issues relating to drugs, alcohol and tobacco, and published by Knowledge•Action•Change. Data are being collected from existing data sources in the published literature, market research and market reports, reports from manufacturers and stock analysts, reviews of national legislation and policy, information from multilateral organisations, civil society organisations, harm reduction organisations, and key national informants.

The information in GSTHR will be relevant and useful, informing for policy-makers, policy analysts, consumers, legislators, regulators, civil society organisations, media, public health workers, academics and researchers, as well as manufacturers in their work.

Knowledge•Action•Change will issue further notices to subscribers to our mail lists and access details when the report is released.

The GSTHR is supported by a grant from the Foundation for a Smoke-Free World.
Don't forget
GFN 2019
13-15 June
next year
in Warsaw